Jennifer Hertzog

Jennifer Hertzog has a diverse work experience in the pharmaceutical industry. Jennifer currently holds the role of Senior Program Manager at Orionis Biosciences, starting in September 2022. Prior to that, they worked at Nuvation Bio as a Principal Scientist from May 2021 to August 2022, where they managed preclinical experimental studies for the development of a small molecule BET inhibitor.

From October 2018 to April 2021, Jennifer was a Discovery Oncology Scientist at The Janssen Pharmaceutical Companies of Johnson & Johnson. In this role, they managed the pre-clinical development of multiple T cell redirection programs targeting prostate cancer. Jennifer also contributed to the preclinical development of a novel T cell redirection platform in solid tumors.

Before that, Jennifer worked at Bristol-Myers Squibb from October 2009 to April 2014 as an Associate Research Scientist II, where they investigated early discovery targets using cellular and molecular biology techniques. Jennifer was responsible for screening target inhibitors and characterizing epigenetic targets.

From January 2009 to October 2009, Jennifer worked as a Biologist at PPD, continuing their responsibilities from Merck & Co., Inc. within the Clinical Assay Management department. At Merck, they worked from June 2006 to December 2008 as a Biologist, supporting clinical trials for vaccines and biologics through high-throughput efficacy testing.

Overall, Jennifer Hertzog's work experience showcases their expertise in preclinical development, oncology research, and assay management in the pharmaceutical industry.

Jennifer Hertzog earned a Bachelor's degree in Biotechnology and Molecular Sciences from Jefferson Health in 2006. Jennifer then pursued a Master of Science (MS) degree in Cell Biology/Biotechnology from the University of the Sciences in Philadelphia, completing it in 2012. Jennifer continued their education at the University of the Sciences in Philadelphia and obtained a Doctor of Philosophy (PhD) in Cell/Cellular and Molecular Biology in 2020.